ESMO: Despite survival miss, Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan

ESMO: Despite survival miss, Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan aliu Mon, 09/16/2024 - 16:14